Vexim has reached the key milestone of 25,000 SpineJack units sold since the market launch of the implant in 2011. This symbolic 25,000 mark in the sales of SpineJack implants officially occurred in the last quarter of 2015.
In October, the company had already announced a new quarterly sales record of €3.6 million for the 3rd quarter 2015, an increase of 44% from the same period in 2014.
Vexim has announced that it has sold 25,000 SpineJack units since the product was launched commercially in 2011. The 25,000 mark was hit in the last quarter of 2015.
The company had previously announced a sales record of €3.6 million for the third quarter of 2015. This was an increase of 44% on this period in 2014.
“To have passed the 25,000 mark in SpineJack implants sold is a major step for Vexim, one that highlights the company’s exponential growth since we launched the device. This excellent performance was made possible by the implementation of a coherent and effective strategy, as well as the involvement of all our teams. Our technology and expertise in spine trauma are now validated by the fact that the SpineJack is used by over 300 customers across Europe. We anticipate that the adoption of our technology will keep expanding. We’re also following on our action plan to obtain the 510(k) regulatory clearance to market SpineJack in the US, which alone accountsfor half of the global spinetrauma market,” says Vincent Gardès, CEO of Vexim.
